Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Effect of extended hours dialysis on markers of chronic kidney disease-mineral and bone disorder in the ACTIVE Dialysis study.

Zhan Z, Smyth B, Toussaint ND, Gray NA, Zuo L, de Zoysa JR, Chan CT, Jin C, Scaria A, Hawley CM, Perkovic V, Jardine MJ, Zhang L.

BMC Nephrol. 2019 Jul 12;20(1):258. doi: 10.1186/s12882-019-1438-3.

2.

Medication non-adherence in a cohort of chronically ill Australians: A case of missed opportunities.

Laba TL, Lung T, Jan S, Scaria A, Usherwood T, Brien JA, A Plant N, Leeder S.

Aust J Gen Pract. 2018 Aug;47(8):556-562.

3.

Rationally designed AAV2 and AAVrh8R capsids provide improved transduction in the retina and brain.

Sullivan JA, Stanek LM, Lukason MJ, Bu J, Osmond SR, Barry EA, O'Riordan CR, Shihabuddin LS, Cheng SH, Scaria A.

Gene Ther. 2018 Jun;25(3):205-219. doi: 10.1038/s41434-018-0017-8. Epub 2018 May 22.

PMID:
29785047
4.

Universal Method for the Purification of Recombinant AAV Vectors of Differing Serotypes.

Nass SA, Mattingly MA, Woodcock DA, Burnham BL, Ardinger JA, Osmond SE, Frederick AM, Scaria A, Cheng SH, O'Riordan CR.

Mol Ther Methods Clin Dev. 2017 Dec 22;9:33-46. doi: 10.1016/j.omtm.2017.12.004. eCollection 2018 Jun 15.

5.

Ocular gene therapy for neovascular AMD: a new era? - Authors' reply.

Campochiaro PA, Heier JS, Kherani S, Le-Halpere A, Scaria A.

Lancet. 2017 Nov 11;390(10108):2140. doi: 10.1016/S0140-6736(17)32424-8. Epub 2017 Nov 9. No abstract available.

PMID:
29143750
6.

Intravitreous injection of AAV2-sFLT01 in patients with advanced neovascular age-related macular degeneration: a phase 1, open-label trial.

Heier JS, Kherani S, Desai S, Dugel P, Kaushal S, Cheng SH, Delacono C, Purvis A, Richards S, Le-Halpere A, Connelly J, Wadsworth SC, Varona R, Buggage R, Scaria A, Campochiaro PA.

Lancet. 2017 Jul 1;390(10089):50-61. doi: 10.1016/S0140-6736(17)30979-0. Epub 2017 May 17. Erratum in: Lancet. 2017 Jul 1;390(10089):28.

PMID:
28526489
7.

AAVS1-Targeted Plasmid Integration in AAV Producer Cell Lines.

Luo Y, Frederick A, Martin JM, Scaria A, Cheng SH, Armentano D, Wadsworth SC, Vincent KA.

Hum Gene Ther Methods. 2017 Jun;28(3):124-138. doi: 10.1089/hgtb.2016.158. Epub 2017 Apr 14.

PMID:
28504553
8.

Soluble FLT1 Gene Therapy Alleviates Brain Arteriovenous Malformation Severity.

Zhu W, Shen F, Mao L, Zhan L, Kang S, Sun Z, Nelson J, Zhang R, Zou D, McDougall CM, Lawton MT, Vu TH, Wu Z, Scaria A, Colosi P, Forsayeth J, Su H.

Stroke. 2017 May;48(5):1420-1423. doi: 10.1161/STROKEAHA.116.015713. Epub 2017 Mar 21.

9.

CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10.

Ruan GX, Barry E, Yu D, Lukason M, Cheng SH, Scaria A.

Mol Ther. 2017 Feb 1;25(2):331-341. doi: 10.1016/j.ymthe.2016.12.006. Epub 2017 Jan 18.

10.

Representativeness of Honeypot Trial Participants to Australasian PD Patients.

HONEYPOT Trial Writing Committee, Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, Liu X, McTaggart S, Morrish AT, Playford G, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW; HONEYPOT Study Collaborative Group.

Perit Dial Int. 2017 Sep-Oct;37(5):516-522. doi: 10.3747/pdi.2016.00065. Epub 2016 Dec 1.

PMID:
27935534
11.

Updates on baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi LS, Ong LM, Irish AB; FAVOURED study team.

Nephrology (Carlton). 2017 Oct;22(10):823-824. doi: 10.1111/nep.12823. No abstract available.

PMID:
27188542
12.

Association between serum hepcidin-25 and primary resistance to erythropoiesis-stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Gummer J, Trengove R, Pascoe EM, Badve SV, Cass A, Clarke P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, Olynyk JK, Ferrari P; HERO Study Collaborative Group.

Nephrology (Carlton). 2017 Jul;22(7):548-554. doi: 10.1111/nep.12815.

PMID:
27171136
13.

The β-Blocker to Lower Cardiovascular Dialysis Events (BLOCADE) Feasibility Study: A Randomized Controlled Trial.

Roberts MA, Pilmore HL, Ierino FL, Badve SV, Cass A, Garg AX, Isbel NM, Krum H, Pascoe EM, Perkovic V, Scaria A, Tonkin AM, Vergara LA, Hawley CM; BLOCADE Study Collaborative Group.

Am J Kidney Dis. 2016 Jun;67(6):902-11. doi: 10.1053/j.ajkd.2015.10.029. Epub 2015 Dec 22.

PMID:
26717861
14.

Analytical Ultracentrifugation as an Approach to Characterize Recombinant Adeno-Associated Viral Vectors.

Burnham B, Nass S, Kong E, Mattingly M, Woodcock D, Song A, Wadsworth S, Cheng SH, Scaria A, O'Riordan CR.

Hum Gene Ther Methods. 2015 Dec;26(6):228-42. doi: 10.1089/hgtb.2015.048. Epub 2015 Oct 15.

PMID:
26414997
15.

Association between serum alkaline phosphatase and primary resistance to erythropoiesis stimulating agents in chronic kidney disease: a secondary analysis of the HERO trial.

Badve SV, Zhang L, Coombes JS, Pascoe EM, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW; HERO Study Collaborative Group.

Can J Kidney Health Dis. 2015 Aug 18;2:33. doi: 10.1186/s40697-015-0066-5. eCollection 2015.

16.

The Effect of Exit-Site Antibacterial Honey Versus Nasal Mupirocin Prophylaxis on the Microbiology and Outcomes of Peritoneal Dialysis-Associated Peritonitis and Exit-Site Infections: A Sub-Study of the Honeypot Trial.

Zhang L, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM, Johnson DW; HONEYPOT Study Collaborative Group.

Perit Dial Int. 2015 Dec;35(7):712-21. doi: 10.3747/pdi.2014.00206. Epub 2015 Jul 29.

17.

Baseline characteristics of the omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study.

Viecelli AK, Pascoe EM, Polkinghorne KR, Hawley CM, Paul-Brent PA, Badve SV, Cass A, Johnson DW, Kerr PG, Mori TA, Scaria A, Hooi SL, Ong ML, Irish AB; FAVOURED Study Team.

Nephrology (Carlton). 2016 Mar;21(3):217-28. doi: 10.1111/nep.12573.

18.

Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.

Shen F, Mao L, Zhu W, Lawton MT, Pechan P, Colosi P, Wu Z, Scaria A, Su H.

Gene Ther. 2015 Nov;22(11):893-900. doi: 10.1038/gt.2015.57. Epub 2015 Jun 19.

19.

The effect of pentoxifylline on oxidative stress in chronic kidney disease patients with erythropoiesis-stimulating agent hyporesponsiveness: Sub-study of the HERO trial.

Zhang L, Coombes J, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM, Johnson DW, On Behalf Of The Hero Study Collaborative Group.

Redox Rep. 2016 Jan;21(1):14-23. doi: 10.1179/1351000215Y.0000000022. Epub 2016 Mar 4.

PMID:
26083328
20.

Genetic diversity is a predictor of mortality in humans.

Bihlmeyer NA, Brody JA, Smith AV, Lunetta KL, Nalls M, Smith JA, Tanaka T, Davies G, Yu L, Mirza SS, Teumer A, Coresh J, Pankow JS, Franceschini N, Scaria A, Oshima J, Psaty BM, Gudnason V, Eiriksdottir G, Harris TB, Li H, Karasik D, Kiel DP, Garcia M, Liu Y, Faul JD, Kardia SL, Zhao W, Ferrucci L, Allerhand M, Liewald DC, Redmond P, Starr JM, De Jager PL, Evans DA, Direk N, Ikram MA, Uitterlinden A, Homuth G, Lorbeer R, Grabe HJ, Launer L, Murabito JM, Singleton AB, Weir DR, Bandinelli S, Deary IJ, Bennett DA, Tiemeier H, Kocher T, Lumley T, Arking DE.

BMC Genet. 2014 Dec 29;15:159. doi: 10.1186/s12863-014-0159-7.

21.

Gene Therapies for Neovascular Age-Related Macular Degeneration.

Pechan P, Wadsworth S, Scaria A.

Cold Spring Harb Perspect Med. 2014 Dec 18;5(7):a017335. doi: 10.1101/cshperspect.a017335. Review.

22.

A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.

Johnson DW, Pascoe EM, Badve SV, Dalziel K, Cass A, Clarke P, Ferrari P, McDonald SP, Morrish AT, Pedagogos E, Perkovic V, Reidlinger D, Scaria A, Walker R, Vergara LA, Hawley CM; HERO Study Collaborative Group.

Am J Kidney Dis. 2015 Jan;65(1):49-57. doi: 10.1053/j.ajkd.2014.06.020. Epub 2014 Aug 10.

PMID:
25115616
23.

Interleukin-17 retinotoxicity is prevented by gene transfer of a soluble interleukin-17 receptor acting as a cytokine blocker: implications for age-related macular degeneration.

Ardeljan D, Wang Y, Park S, Shen D, Chu XK, Yu CR, Abu-Asab M, Tuo J, Eberhart CG, Olsen TW, Mullins RF, White G, Wadsworth S, Scaria A, Chan CC.

PLoS One. 2014 Apr 29;9(4):e95900. doi: 10.1371/journal.pone.0095900. eCollection 2014.

24.

Translational fidelity of intrathecal delivery of self-complementary AAV9-survival motor neuron 1 for spinal muscular atrophy.

Passini MA, Bu J, Richards AM, Treleaven CM, Sullivan JA, O'Riordan CR, Scaria A, Kells AP, Samaranch L, San Sebastian W, Federici T, Fiandaca MS, Boulis NM, Bankiewicz KS, Shihabuddin LS, Cheng SH.

Hum Gene Ther. 2014 Jul;25(7):619-30. doi: 10.1089/hum.2014.011. Epub 2014 Apr 28.

PMID:
24617515
25.

Aurintricarboxylic acid increases yield of HSV-1 vectors.

Pechan P, Ardinger J, Ketavarapu J, Rubin H, Wadsworth SC, Scaria A.

Mol Ther Methods Clin Dev. 2014 Feb 19;1:6. doi: 10.1038/mtm.2013.6. eCollection 2014.

26.

Antibacterial honey for the prevention of peritoneal-dialysis-related infections (HONEYPOT): a randomised trial.

Johnson DW, Badve SV, Pascoe EM, Beller E, Cass A, Clark C, de Zoysa J, Isbel NM, McTaggart S, Morrish AT, Playford EG, Scaria A, Snelling P, Vergara LA, Hawley CM; HONEYPOT Study Collaborative Group.

Lancet Infect Dis. 2014 Jan;14(1):23-30. doi: 10.1016/S1473-3099(13)70258-5. Epub 2013 Oct 10.

PMID:
24119840
27.

The HONEYPOT randomized controlled trial statistical analysis plan.

Pascoe EM, Lo S, Scaria A, Badve SV, Beller EM, Cass A, Hawley CM, Johnson DW.

Perit Dial Int. 2013 Jul-Aug;33(4):426-35. doi: 10.3747/pdi.2012.00310.

28.

Prevalence of neutralizing factors against adeno-associated virus types 2 in age-related macular degeneration and polypoidal choroidal vasculopathy.

Cheng Y, Huang L, Li X, Qi H, Zhou P, Yu W, Jiang YA, Wadsworth S, Scaria A.

Curr Gene Ther. 2013 Jun 1;13(3):182-8.

PMID:
23590636
29.

Do echocardiographic parameters predict mortality in patients with end-stage renal disease?

Stallworthy EJ, Pilmore HL, Webster MW, Sidhu KK, Curry EM, Brown P, Scaria A.

Transplantation. 2013 May 27;95(10):1225-32. doi: 10.1097/TP.0b013e31828dbbbe.

PMID:
23542473
30.

Local gene delivery of heme oxygenase-1 by adeno-associated virus into osteoarthritic mouse joints exhibiting synovial oxidative stress.

Kyostio-Moore S, Bangari DS, Ewing P, Nambiar B, Berthelette P, Sookdeo C, Hutto E, Moran N, Sullivan J, Matthews GL, Scaria A, Armentano D.

Osteoarthritis Cartilage. 2013 Feb;21(2):358-67. doi: 10.1016/j.joca.2012.11.002. Epub 2012 Nov 11.

31.

Development of a cellular model of rod opsin retinitis pigmentosa.

Adamowicz M, Song A, Wadsworth S, Scaria A, O'Riordan C.

Adv Exp Med Biol. 2012;723:573-9. doi: 10.1007/978-1-4614-0631-0_73. No abstract available.

PMID:
22183380
32.

AAV5-mediated sFLT01 gene therapy arrests retinal lesions in Ccl2(-/-)/Cx3cr1(-/-) mice.

Tuo J, Pang JJ, Cao X, Shen D, Zhang J, Scaria A, Wadsworth SC, Pechan P, Boye SL, Hauswirth WW, Chan CC.

Neurobiol Aging. 2012 Feb;33(2):433.e1-10. doi: 10.1016/j.neurobiolaging.2011.01.009. Epub 2011 Mar 12.

33.

sFLT01: a novel fusion protein with antiangiogenic activity.

Bagley RG, Kurtzberg L, Weber W, Nguyen TH, Roth S, Krumbholz R, Yao M, Richards B, Zhang M, Pechan P, Schmid S, Scaria A, Kaplan J, Teicher BA.

Mol Cancer Ther. 2011 Mar;10(3):404-15. doi: 10.1158/1535-7163.MCT-10-0813. Epub 2011 Jan 20.

34.

Preclinical safety evaluation of AAV2-sFLT01- a gene therapy for age-related macular degeneration.

Maclachlan TK, Lukason M, Collins M, Munger R, Isenberger E, Rogers C, Malatos S, Dufresne E, Morris J, Calcedo R, Veres G, Scaria A, Andrews L, Wadsworth S.

Mol Ther. 2011 Feb;19(2):326-34. doi: 10.1038/mt.2010.258. Epub 2010 Nov 30.

35.

Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule.

Lukason M, DuFresne E, Rubin H, Pechan P, Li Q, Kim I, Kiss S, Flaxel C, Collins M, Miller J, Hauswirth W, Maclachlan T, Wadsworth S, Scaria A.

Mol Ther. 2011 Feb;19(2):260-5. doi: 10.1038/mt.2010.230. Epub 2010 Oct 26.

36.

Probing the vibrational dynamics of high-lying electronic states using pump-degenerate four-wave mixing.

Liebers J, Scaria A, Materny A, Kleinekathöfer U.

Phys Chem Chem Phys. 2010 Feb 14;12(6):1351-6. doi: 10.1039/b917967d. Epub 2009 Dec 7.

PMID:
20119613
37.

Cytotoxic T lymphocyte responses to transgene product, not adeno-associated viral capsid protein, limit transgene expression in mice.

Siders WM, Shields J, Kaplan J, Lukason M, Woodworth L, Wadsworth S, Scaria A.

Hum Gene Ther. 2009 Jan;20(1):11-20. doi: 10.1089/hum.2008.055.

38.

Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization.

Pechan P, Rubin H, Lukason M, Ardinger J, DuFresne E, Hauswirth WW, Wadsworth SC, Scaria A.

Gene Ther. 2009 Jan;16(1):10-6. doi: 10.1038/gt.2008.115. Epub 2008 Jul 17.

PMID:
18633446
39.

Ultrafast vibrational dynamics observed in higher electronic excited states of iodine using pump-UV DFWM spectroscopy.

Scaria A, Namboodiri V, Konradi J, Materny A.

Phys Chem Chem Phys. 2008 Feb 21;10(7):983-9. doi: 10.1039/b715814a. Epub 2007 Dec 10.

PMID:
18259637
40.

Influence of electronic resonances on mode selective excitation with tailored laser pulses.

Konradi J, Gaal A, Scaria A, Namboodiri V, Materny A.

J Phys Chem A. 2008 Feb 21;112(7):1380-91. doi: 10.1021/jp0745079. Epub 2008 Jan 29.

PMID:
18225867
41.

Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation.

Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, Kaplan B, Von Herrath M, Womer K, Atkinson MA.

Diabetes. 2008 Feb;57(2):405-14. Epub 2007 Nov 26.

42.

Characterization of in vitro antimurine thymocyte globulin-induced regulatory T cells that inhibit graft-versus-host disease in vivo.

Ruzek MC, Waire JS, Hopkins D, Lacorcia G, Sullivan J, Roberts BL, Richards SM, Nahill SR, Williams JM, Scaria A, Dzuris J, Shankara S, Garman RD.

Blood. 2008 Feb 1;111(3):1726-34. Epub 2007 Nov 19.

43.

Vibrational dynamics of excited electronic states of molecular iodine.

Scaria A, Namboodiri V, Konradi J, Materny A.

J Chem Phys. 2007 Oct 14;127(14):144305.

PMID:
17935393
44.

Delivery of CFTR by adenoviral vector to cystic fibrosis mouse lung in a model of chronic Pseudomonas aeruginosa lung infection.

Van Heeckeren AM, Scaria A, Schluchter MD, Ferkol TW, Wadsworth S, Davis PB.

Am J Physiol Lung Cell Mol Physiol. 2004 Apr;286(4):L717-26. Epub 2003 Sep 26.

45.

Myocardial expression of baculoviral p35 alleviates doxorubicin-induced cardiomyopathy in rats.

Date T, Luo Z, Yamakawa M, Belanger AJ, Scaria A, Cheng SH, Gregory RJ, Mochizuki S, Jiang C.

Hum Gene Ther. 2003 Jul 1;14(10):947-57.

PMID:
12869213
47.

Demonstration of feasibility of in vivo gene therapy for Gaucher disease using a chemically induced mouse model.

Marshall J, McEachern KA, Kyros JA, Nietupski JB, Budzinski T, Ziegler RJ, Yew NS, Sullivan J, Scaria A, van Rooijen N, Barranger JA, Cheng SH.

Mol Ther. 2002 Aug;6(2):179-89.

48.

Adenovirus-mediated expression of p35 prevents hypoxia/reoxygenation injury by reducing reactive oxygen species and caspase activity.

Date T, Belanger AJ, Mochizuki S, Sullivan JA, Liu LX, Scaria A, Cheng SH, Gregory RJ, Jiang C.

Cardiovasc Res. 2002 Aug 1;55(2):309-19.

PMID:
12123770
49.
50.

Enhancement of Fas ligand-induced inhibition of neointimal formation in rabbit femoral and iliac arteries by coexpression of p35.

Luo Z, Garron T, Palasis M, Lu H, Belanger AJ, Scaria A, Vincent KA, Date T, Akita GY, Cheng SH, Barry J, Gregory RJ, Jiang C.

Hum Gene Ther. 2001 Dec 10;12(18):2191-202.

PMID:
11779403

Supplemental Content

Loading ...
Support Center